Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications

Alexander Laarman · Fin Milder · Jos van Strijp · Suzan Rooijakkers

Abstract The plasma proteins of the complement system are essential in the innate immune response against bacteria. Complement labels bacteria with opsonins to support phagocytosis and generates chemoattractants to attract phagocytes to the site of infection. In turn, bacterial human pathogens have evolved different strategies to specifically impair the complement response. Here, we review the large arsenal of complement inhibitors produced by the gram-positive pathogens Staphylococcus aureus and Group A Streptococcus. We discuss how these bacterial molecules provide us with new tools to treat both infectious and inflammatory disease conditions in humans.

Keywords Complement · Immune evasion · Bacteria · Innate immunity

The innate immune system plays a critical role in our host defense against invading pathogens. This system consists of three different parts: (a) the complement system, (b) phagocytes, and (c) antimicrobial peptides. The three major functions of the complement cascade in innate immunity are (1) to label pathogens or immunogenic particles with C3b and iC3b to facilitate phagocytic uptake via complement receptors, (2) to attract phagocytes by producing chemoattractant C5a, and (3) to directly lyse gram-negative bacteria through membrane attack complex (MAC; C5b-9) formation (Fig. 1) [1]. Complement is initiated by two specific recognition pathways, the classical and lectin pathway, which are amplified by the alternative pathway. All three pathways converge at the formation of the C3 convertases. These bimolecular surface-bound enzyme complexes catalyze the key reaction in complement activation: cleavage of complement protein C3 into C3a, a chemoattractant with bactericidal activity [2–4], and C3b [5]. Convertase formation is pivotal in complement activation since C3b and its inactive derivative iC3b facilitate phagocytosis. Furthermore, the deposited C3b can form new convertases, thereby amplifying the opsonization process. Subsequently, the high concentrations of locally deposited C3b induce a shift in substrate specificity of the convertase to complement protein C5. The cleavage products of C5 are C5a, a potent chemoattractant, and C5b that initiates the lytic pathway. Due to the resulting C5a gradient, neutrophils migrate toward the site of infection and phagocytose the invaders. Neutrophils kill ingested particles intracellularly by the production of reactive oxygen species and the release of granule constituents such as proteolytic enzymes and antimicrobial peptides. These peptides are also released into the extracellular space to kill microorganisms extracellularly [6]. Together, these complement-mediated events are responsible for the efficient elimination of invading bacteria.

It has become increasingly evident that pathogens have developed various ways to evade the constant attack of the complement system. Pathogens produce proteins that modulate all stages of the complement cascade. These proteins inhibit complement recognition and amplification, cleave complement proteins, or interfere with complement receptor interactions on phagocytes. A number of reviews have been published on these specific topics [7–9]. In this
paper, we give a broad overview of the complement evasion strategies of the two most important gram-positive human pathogens *Staphylococcus aureus* and group A *Streptococcus* (GAS), and we discuss the potential of these bacterial complement modulators as therapeutic agents.

**Modulation of complement recognition and activation**

The classical and lectin pathways of complement ensure immediate recognition of invading bacteria as nonself. The C1-complex (classical pathway) recognizes bacterium-bound IgG and IgM while mannose-binding lectins and ficolins (lectin pathway) bind bacterial sugar moieties. *S. aureus* expresses two surface-anchored proteins that impair IgG function (Fig. 2a): staphylococcal protein A (SpA) and staphylococcal immunoglobulin-binding protein (Sbi). SpA is a surface protein with four or five immunoglobulin-binding repeat domains. Each domain can bind the Fc-part of IgG, thereby blocking the interaction with Fc receptors on neutrophils in vitro [10, 11]. Sbi consists of four small domains, of which two (Sbi-I and Sbi-II) can bind IgG [12]. Next to blocking Fc-receptor-mediated phagocytosis, Sbi has been suggested to block binding of C1q and subsequent activation of the classical pathway.

Another strategy to prevent recognition is to eliminate opsonic molecules from the bacterial surface by proteolytic degradation. Staphylokinase (SAK) is a secreted protein that binds and activates surface-bound plasminogen into plasmin, which may enhance bacterial invasion through host tissues. Interestingly, it has been shown that SAK is anti-opsonic as well. SAK-mediated plasmin deposition on the bacterial surface can cleave IgG and C3b and thereby inhibit phagocytosis in vitro [13]. GAS expresses several proteases that directly cleave IgG: the Endoglycosidase in *Streptococcus pyogenes* (EndoS) specifically hydrolyzes the asparagine-linked glycan in the CH2 domain of IgG; the IgG-degrading enzyme of *S. pyogenes* (IdoS or Mac-1), Mac-2, and streptococcal pyrogenic exotoxin B (SpeB) all cleave IgG in the hinge region [14, 15].

**Modulation of complement amplification**

Formation of the C3 convertases is elemental for amplification of complement activation and downstream immune...
responses. There are three ways by which *S. aureus* and GAS modulate this central step in the complement cascade (Fig. 2b):

1. **Cleavage of C3**

   The abundant GAS protease SpeB is, next to cleaving IgG, involved in breakdown of C3. Comparison of wild-type GAS and a SpeB knockout showed that SpeB blocks neutrophil recruitment to the site of infection and subsequent phagocytosis and bacterial clearance in vivo [16, 17]. The *S. aureus* surface protein clumping factor A (ClfA) can bind the human C3b protease factor I (fI), thereby enhancing cleavage of surface-bound C3b into iC3b in vitro [18].

2. **Direct inactivation of C3 convertases**

   Convertases are the major complement target among *S. aureus* immune evasion strategies. *S. aureus* secretes five different molecules that directly inhibit these central enzyme complexes. Staphylococcal complement inhibitor (SCIN) and its homologues SCIN-B and SCIN-C are highly effective C3 convertase inhibitors that block conversion of C3 and subsequent phagocytosis and C5a formation in vitro at low concentrations [19]. The alternative pathway C3 convertase consists of a cofactor (C3b) which is loosely bound to the protease subunit (Bb). Recent structural studies revealed that the small 10-kD SCIN protein fixes the convertase conformation and as such hampers a critical rearrangement of the protease subunit Bb in relation to substrate C3 [20, 21]. The action of SCIN on the classical pathway convertase remains to be resolved but seems to be caused by a stabilizing mechanism as well [19]. Extracellular fibrinogen-binding protein (Efb) and extracellular complement-binding protein (EcB) can modulate the alternative pathway convertase by binding to the C3b molecule directly [22]. The crystal structures of both molecules in complex with the C3d domain of C3 have revealed their exact binding sites [23, 24]. Interestingly, since the C3d fragment of C3 is involved in stimulation of adaptive immune responses, it was recently suggested that Efb functions as an adaptive immunity modulator as well [25].

3. **Binding or cleavage of human convertase regulators**

   To protect host tissues from excessive complement activity, humans express complement regulators that down-regulate convertase activity. A large number of pathogens express molecules that attract these regulators to their surface. The staphylococcal IgG-binding molecule Sbi has a diverse role in complement modulation. Next to its two IgG-binding domains, Sbi-III and IV, it can also bind to C3 [26]. Furthermore, Sbi binds the human complement regulators factor H (FH) and factor H-related proteins and can form a stable tripartite complex with C3 and FH [27]. Altogether, these actions result in inhibition of the alternative pathway in vitro. The streptococcal M protein is a multifunctional surface molecule that binds four different human convertase regulators: FH, FHL1, C4BP, and CD46 while SpeB cleaves the positive convertase regulator, properdin.
terminus, the protein comprises four repeat regions: hyper-variable (a), variable (b), and conserved (c and d). Depending on the M type, the hypervariable region can bind FH, FHL-1 [31], and C4BP [32]. By binding these complement regulators, M protein limits deposition of C4b and C3b increasing GAS resistance to phagocytosis [33]. In vivo studies with strains expressing mutated M protein indicate that protein is an important GAS virulent factor [34]. Finally, SpeB also digests the positive convertase regulator propersin, making the streptococci more resistant to neutrophil killing in vitro [35].

Modulation of the complement effector functions: inhibiting C5 activation and neutrophil migration

In the final step of the complement cascade, the C5 convertases cleave C5 to generate the important chemoattractant C5a that directs neutrophils to the site of infection. *S. aureus* and GAS use various approaches to evade the C5a-mediated immune responses (Fig. 3). Staphylococcal superantigen-like 7 (SSL7) is a secreted protein that specifically binds to C5 [36] and thereby prevents C5 activation into C5b and C5a in vitro (J. Bestebroer, personal communication). Efb and Ecb are very potent inhibitors of C5a responses in vitro and in vivo [22]. These molecules elicit their immune modulating capacity by binding the C3b part of the C5 convertase complex. GAS uses the cell-associated peptidase ScpA to directly target C5a. ScpA cleaves C5a and blocks chemotaxis of phagocytes toward the site of infection [37]. In a mouse pneumonia model, it was shown that the ScpA knockout mutant was less virulent than wild-type GAS [38]. Modulation of C5a responses by *S. aureus* proceeds through inhibition of the C5a receptor (C5aR). The chemotaxis inhibitory protein of *S. aureus* (CHIPS) is a 14-kD excreted protein that effectively blocks neutrophil recruitment toward C5a in vitro by binding the C5aR with high (nanomolar) affinity [39]. The recent nuclear magnetic resonance (NMR) structure of CHIPS in complex with the N terminus of the C5aR showed two sulfated tyrosine (residues 11 and 14) of the C5aR to be essential for the interaction in between the C5aR and the inhibitor CHIPS [40].

Cleavage of C5 also results in formation of C5b, the molecule that initiates the formation of the membrane attack complex (C5b-9). This complex can damage target cells such as gram-negative bacteria. MAC formation is often monitored in vitro by a so-called hemolytic assay in which erythrocytes (often sheep or rabbit) are used as a direct target for complement activation and hemolysis. The *S. aureus* proteins SCIN, Efb, Ecb, and SSL7 block MAC-mediated erythrocyte hemolysis since they inhibit the complement cascade upstream of MAC formation. The highly variable streptococcal inhibitor of complement (SIC) from GAS was found to specifically block formation of the MAC by binding to the C5b-7 complex and preventing erythrocyte hemolysis in vitro [41]. The relevance of MAC inhibition by gram-positive bacteria remains unclear since they are naturally protected from lysis via their thick cell wall. The SIC molecule also interacts with several human antimicrobial peptides (LL-37, defensins) [42], and this might be more relevant for protecting GAS from host immunity.

Complement evasion molecules as tools and targets in therapy

Bacterial complement modulators have important applications for the treatment of inflammatory diseases where complement is directed against our own cells [43]. Per definition, molecules that counteract acute innate immune...
mechanisms are anti-inflammatory compounds. As opposed to several bacterial toxins, the high specificity and the mode of action that depends entirely on protein–protein interactions makes these nontoxic proteins suitable anti-inflammatory drugs. It is tempting to speculate that these molecules could be used as injectables in acute inflammatory disorders. However, since these molecules are derived from common human pathogens, pre-existing antibodies severely complicate this approach. Furthermore, a number of the described molecules appear to be human-specific which complicates functional studies in vivo [19, 44, 45] However, the immunological molecules that are attacked by these factors might prove to be the essential targets to tackle in anti-inflammatory therapy. We feel that the bacterial products could be used as an indicator of the “Achilles heel” of the human immune system—almost at the atomic level. Especially, since the 3-D structures of a number of molecules in context with their target are now elucidated in several crystallographic and NMR studies [19, 20, 25, 40, 46], this opens new possibilities for smart design of small-molecule therapeutics. Thus, we can copy these evolutionary-designed molecules to counteract the detrimental effects of complement activation in inflammatory disease states.

Next to their potential as anti-inflammatory compounds, we believe that targeting of complement evasion molecules should be included in future strategies to fight bacterial infections. The evasion molecules described above not only suppress natural immunity during an infection but also hamper the current attempts to create effective vaccines. The efficacy of vaccines is held back by the existing bacterial immune evasion strategies since they prevent neutrophils or complement to reach the site of infection. Even with sufficient opsonic or bactericidal antibodies on the bacterium, nothing will happen if the innate immune effectors are absent. Since immune evasion molecules are essentially vaccine evasion molecules, we propose that these molecules should be specifically targeted in the vaccine. Alternatively, we could think of ways to neutralize these molecules and use that in novel strategies to fight infectious diseases. In fact, we propose to inhibit the inhibitor and thereby decrease the advantage of the bacterium over the host.

So, taken together, the smart attack of the bacteria on our complement system might hold clues for future drugs in both inflammatory as well as infectious diseases. In this way, we could turn this powerful escape mechanism into our own advantage.

Acknowledgments A.L., J.v.S., and S.H.M.R. are supported by grants of the Netherlands Organization for Scientific Research (NWO-TOP and NWO-Veni). S.H.M.R. is also funded by the European Molecular Biology Organization.

Conflict of interest statement The authors declare that they have no conflict of interests.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058–1066
2. Hartmann K, Henz BM, Krüger-Krasagakes S, Köhl J, Burger R, Guhl S, Haase I, Lippert U, Zuberbier T (1997) C3a and C5a stimulate chemotaxis of human mast cells. Blood 89:2863–2870
3. Daffern PJ, Pfeifer PH, Ember JA, Hugi TE (1995) C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 181:2119–2127
4. Nordahl EA, Rydengård V, Nyberg P, Nitsche DP, Mörgelin M, Malmsten M, Bjärcck L, Schmidtchen A (2004) Activation of the complement system generates antibacterial peptides. Proc Natl Acad Sci USA 101:16879–16884
5. Gros P, Milder F, Janssen B (2008) Complement driven by conformational changes. Nat Rev Immunol 8:48–58
6. Borregaard N, Sorensen OE, Theiligard-Mönch K (2007) Neutrophil granules: a library of innate immunity proteins. Trends Immunol 28:340–345
7. Blom AM, Hallström T, Riesbeck K (2009) Complement evasion strategies of pathogens—acquisition of inhibitors and beyond. Mol Immunol 46:2808–2817
8. Lambris JD, Ricklin D, Geisbrecht BV (2008) Complement evasion by human pathogens. Nat Rev Microbiol 6:132–142
9. Geisbrecht BV (2008) Staphylococcal complement inhibitors: biological functions, recognition of complement components, and potential therapeutic implications. Adv Exp Med Biol 632:221–236
10. Forsgren A, Sjoquist J (1966) "Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin. J Immunol 97:822–827
11. Goward CR, Seawen MD, Murphy JP, Atkinson T (1993) Molecular evolution of bacterial cell-surface proteins. Trends Biochem Sci 18:136–140
12. Atkins KL, Burman JD, Chamberlain ES, Cooper JE, Poutrel B, Bagby S, Jenkins ATA, Feil EJ, Van den Elsen JMH (2008) S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. Mol Immunol 45:1600–1611
13. Rooijakkers SHM, van Wamel WJB, Ruyken M, van Kessel KPM, van Strijp JAG (2005) Anti-opsonic properties of staphylokinase. Microbes Infect 7:476–484
14. Collin M, Olsen A (2001) Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect Immun 69:7187–7189
15. Collin M, Olsen A (2001) EndoS, a novel secreted protein from Streptococcus pyogenes with endoglucosidase activity on human IgG. EMBO J 20:3046–3055
16. Lukomska S, Burns EH, Wyde PR, Podbielski A, Rurangirwa J, Moore-Poveda DK, Musser JM (1998) Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs. Infect Immun 66:771–776
17. Terao Y, Mori Y, Yamaguchi M, Shimizu Y, Ooe K, Hamada S, Kawabata S (2008) Group A streptococcal cysteine protease
degrades C3 (C3b) and contributes to evasion of innate immunity. J Biol Chem 283:6253–6260
18. Hair PS, Ward MD, Semmes OJ, Foster TJ, Cunnion KM (2008) Staphylococcal aureus eluding factor A binds to complement regulator factor I and increases factor I cleavage of C3b. J Infect Dis 198:125–133
19. Rooijakkers SHM, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, van Willem JB, Wamel KPM, van Kessel J, van Strijp AG et al (2005) Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol 6:920–927
20. Rooijakkers SHM, Wu J, Ruyken M, van Domselaar R, Planken KL, Tzekou A, Ricklin D, Lambris JD, Janssen BJC, van Strijp JAG, Gros P (2009) Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol 10:721–727
21. Ricklin D, Tzekou A, García BL, Hammel M, McWhorter WJ, Sfyroera G, Wu Y, Hombers M, Herbert AP, Barlow PN, Geisbrecht BV, Lambris JD (2009) A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J Immunol 183:2565–2574
22. Jongerius I, Köh J, Pandey MK, Ruyken M, Van Kessel KPM, Van Strijp JAG, Rooijakkers SHM (2007) Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med 204:2461–2471
23. Hammel M, Sfyroera G, Ricklin D, Magotti P, Lambris JD, Geisbrecht BV (2007) A structural basis for complement inhibition by Staphylococcus aureus. Nat Immunol 8:430–437
24. Hammel M, Sfyroera G, Pyppaopoulos S, Ricklin D, Ramyar KX, Pop M, Jin Z, Lambris JD, Geisbrecht BV (2007) Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. J Biol Chem 282:30051–30061
25. Ricklin D, Ricklin-Lichtesteiner SK, Markiewski MM, Geisbrecht BV, Lambris JD (2008) Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. J Immunol 181:7463–7467
26. Burman JD, Leung E, Atkins KL, O’Seaghdha MN, Lango L, Bernardo P, Bagby S, Svergun DJ, Foster TJ, Isenman DE, van den Elsen JM (2008) Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by Staphylococcus aureus. J Biol Chem 283:17579–17593
27. Haupt K, Reuter M, van den Elsen J, Burman J, Halbich S, Richter J, Sørkka C, Zipfel PF (2008) The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement Factor H and C3b. PLoS Pathog 4:e1000250
28. Robinson JH, Khoe MA (1992) Group A streptococcal M proteins: virulence factors and protective antigens. Immunol Today 13:362–367
29. Fischetti VA (1989) Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 2:285–314
30. McNamara C, Zinkernagel AS, Maichebeuf P, Cunningham MW, Nizet V, Ghosh P (2008) Coiled-coil irregularities and instabilities in group A Streptococcus M1 are required for virulence. Science 319:1405–1408
31. Kotarsky H, Hellwage J, Johnsson E, Sørkka C, Svensson HG, Lindahl G, Sjobring U, Zipfel PF (1998) Identification of a domain in human factor H and factor H-like protein-1 required for the interaction with staphylococcal M proteins. J Immunol 160:3349–3354
32. Johnsson E, Thern A, Dahlback B, Heden LO, Wikstrom M, Lindahl G (1996) A highly variable region in members of the streptococcal M protein family binds the human complement regulator C4BP. J Immunol 157:3021–3029
33. Carlsson F, Berggard K, Stalhammer-Carlemalm M, Lindahl G (2003) Evasion of phagocytosis through cooperation between two ligand-binding regions in Streptococcus pyogenes M protein. J Exp Med 198:1057–1068
34. Ashbaugh CD, Warren HB, Carey VJ, Wessels MR (1998) Molecular analysis of the role of the group A streptococcal cytotoxic protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. J Clin Invest 102:550–560
35. Tsao N, Tsai W, Lin Y, Chuang W, Wang C, Kuo C (2006) Staphylococcal pyrogenic exotoxin B cleaves properdin and inhibits complement-mediated opsonophagocytosis. Biochem Biophys Res Commun 339:779–784
36. Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD (2005) The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J Immunol 174:2926–2933
37. Wexler DE, Chenoweth DE, Cleary PP (1985) Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci USA 82:8144–8148
38. Husmann LK, Yang DL, Hollingshead SK, Scott JR (1997) Role of putative virulence factors of Streptococcus pyogenes in mouse models of long-term throat colonization and pneumonia. Infect Immun 65:1422–1430
39. Postma B, Kleibeuker W, Poppelmier MJJG, Boonstra M, Van Kessel KPM, Van Strijp JAG, De Haas CJC (2005) Residues 10–18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus. J Biol Chem 280:2020–2027
40. Ippel JH, De Haas CJC, Bunschoten A, Van Strijp JAG, Kruijtzer JAW, Liskamp RMJ, Kemmink J (2009) Structure of the tyrosine-sulfated C5a receptor N terminus in complex with chemotaxis inhibitory protein of Staphylococcus aureus. J Biol Chem 284:12363–12372
41. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ (2001) Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology 103:390–398
42. Frick IM, Axessson P, Rasmussen M, Schmidtchen A, Björck L (2003) SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J Biol Chem 278:14301–14307
43. Haas JF, Hugenschmidt C, Liskamp RMJ, Kemmink J (2004) A structural basis for the staphylococcal complement inhibitor. J Biol Chem 279:28166–28171
44. de Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJB, Heezius EC, Poppelmier MJ, Van Kessel KP, Van Strijp JAG (2004) Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med 199:687–695
45. Gladysheva IP, Turner RB, Sazonova IV, Liu L, Reed GL (2003) Coevolutionary patterns in plasminogen activation. Proc Natl Acad Sci USA 100:9168–9172
46. Haas JP, de Haas CJ, Kleibeuker W, Poppelmier MJ, Van Kessel KPM, Kruijtzer JA, Liskamp RM, Van Strijp JAG (2004) N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formulated peptide receptor but not C5a receptor. J Immunol 173:5704–5711
47. Kimura Y, Miwa T, Zhou L, Song WC (2008) Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 111:732–740
48. Hourcade DE (2006) The role of properdin in the assembly of the alternative pathway C3 convertase. J Biol Chem 281:2128–2132